List of Oxlumo drug patents
Oxlumo is owned by Alnylam Pharms Inc.
Oxlumo contains Lumasiran Sodium.
Oxlumo has a total of 14 drug patents out of which 0 drug patents have expired.
Oxlumo was authorised for market use on 23 November, 2020.
Oxlumo is available in solution;subcutaneous dosage forms.
Oxlumo can be used as treatment of primary hyperoxaluria type 1 (ph1).
Drug patent challenges can be filed against Oxlumo from November, 2024.
The generics of Oxlumo are possible to be released after 20 November, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(5 years from now) | |
| US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
| US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(6 years from now) | |
| US10487330 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(11 years from now) | |
| US11060093 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(11 years from now) | |
| US10465195 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(11 years from now) | |
| US9828606 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(11 years from now) | |
| US10612024 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(12 years from now) | |
| US10612027 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(12 years from now) | |
| US11401517 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(12 years from now) | |
| US11446380 | ALNYLAM PHARMS INC | Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
Oct, 2035
(12 years from now) | |
| US10478500 | ALNYLAM PHARMS INC | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression |
Oct, 2035
(12 years from now) | |
| US11261447 | ALNYLAM PHARMS INC | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
Nov, 2038
(15 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10435692 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 23, 2027 |
| New Chemical Entity Exclusivity (NCE) | Nov 23, 2025 |
| New Indication (I) | Oct 6, 2025 |
Drugs and Companies using LUMASIRAN SODIUM ingredient
NCE-1 date: November, 2024
Market Authorisation Date: 23 November, 2020
Treatment: Treatment of primary hyperoxaluria type 1 (ph1)
Dosage: SOLUTION;SUBCUTANEOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic